We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
Read MoreHide Full Article
We expect Johnson & Johnson (JNJ - Free Report) to beat expectations when it reports first-quarter 2022 results on Apr 19, before market open. In the last-reported quarter, the company delivered an earnings surprise of 0.47%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 7.77%, on average.
J&J’s stock has risen 5.8% this year so far compared with an increase of 8.4% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
J&J’s Pharma segment is expected to have continued to outperform the market led by increased penetration and new indications across key products such as Darzalex and Stelara.
The Zacks Consensus Estimate for Darzalex and Stelara is pegged at $1.71 billion and $2.43 billion, respectively.
Other core products like Invega Sustenna/Xeplion/Invega Trinza/Trevicta and new drugs, Erleada and Tremfya might have contributed significantly to sales growth. J&J’s single-dose COVID-19 vaccine is also likely to have contributed to sales growth. A booster shot of the vaccine was authorized in October 2021, which is likely to have boosted sales.
Improvement in sales of some other key drugs like Xarelto seen in the past few quarters is likely to have continued into the first quarter. The Zacks Consensus Estimate for Xarelto is $607 million.
Rising competitive pressure in the United States to new oral competition is likely to have hurt sales of key drug, Imbruvica in the first quarter. The Zacks Consensus Estimate for Imbruvica is $1.13 billion.
Generic/biosimilar competition for drugs like Zytiga, Procrit/Eprex and Remicade is likely to have hurt the top line.
The Zacks Consensus Estimate for J&J’s Pharmaceuticals unit is $13.8 billion.
With regard to the Medical Devices segment, COVID-19 headwinds and hospital staffing shortages are likely to have continued to hurt procedure volume trends in the first quarter. The Zacks Consensus Estimate for J&J’s Medical Devices segment is $6.8 billion.
In the Consumer Healthcare segment, the improving trend seen in the last couple of quarters is likely to have continued. However, external supply constraints (due to raw material availability and labor shortages) are likely to have continued to hurt sales of the skin health and beauty franchise.
The Zacks Consensus Estimate for J&J’s Consumer Healthcare segment is $3.58 billion.
J&J plans to separate its Consumer Health segment into a new publicly-traded company
Management might announce key executive leadership appointments for the new Consumer Health company on the first-quarter conference call and may also announce the new company name and headquarters location.
On the fourth-quarter conference call, its new chief executive officer (CEO) Joaquin Duato had said the company is taking a more aggressive stance on M&A activity as its strong cash position will help it pursue tuck-in M&A to grow its business. An update is expected on the first-quarter conference call.
Earnings Whispers
Our proven model predicts an earnings beat for J&J in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: J&J’s Earnings ESP is +1.14% as the Most Accurate Estimate of $2.64 is higher than the Zacks Consensus Estimate of $2.61. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: J&J has a Zacks Rank #3
Other Stocks to Consider
Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around:
Merck’s stock has risen 14.4% this year so far. Merck topped earnings estimates in two of the last four quarters. Merk has a four-quarter earnings surprise of 5.33%, on average. MRK is scheduled to release its first-quarter 2022 results on Apr 28.
Lilly (LLY - Free Report) has an Earnings ESP of +7.38% and a Zacks Rank #3.
Lilly’s stock has rallied 9.7% this year so far. Lilly missed earnings estimates in each of the last four quarters. Lilly has a four-quarter negative earnings surprise of 3.92%, on average. LLY is scheduled to release its first-quarter 2022 results on Apr 28.
AbbVie (ABBV - Free Report) with an Earnings ESP of +0.48% and a Zacks Rank #3.
AbbVie’s stock has surged 22.2% in the past year. AbbVie topped earnings estimates in three of the last four quarters. AbbVie has a four-quarter earnings surprise of 2.55%, on average. ABBV is scheduled to release its first-quarter 2022 results on Apr 29.
Image: Bigstock
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
We expect Johnson & Johnson (JNJ - Free Report) to beat expectations when it reports first-quarter 2022 results on Apr 19, before market open. In the last-reported quarter, the company delivered an earnings surprise of 0.47%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 7.77%, on average.
Johnson & Johnson Price and EPS Surprise
Johnson & Johnson price-eps-surprise | Johnson & Johnson Quote
J&J’s stock has risen 5.8% this year so far compared with an increase of 8.4% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
J&J’s Pharma segment is expected to have continued to outperform the market led by increased penetration and new indications across key products such as Darzalex and Stelara.
The Zacks Consensus Estimate for Darzalex and Stelara is pegged at $1.71 billion and $2.43 billion, respectively.
Other core products like Invega Sustenna/Xeplion/Invega Trinza/Trevicta and new drugs, Erleada and Tremfya might have contributed significantly to sales growth. J&J’s single-dose COVID-19 vaccine is also likely to have contributed to sales growth. A booster shot of the vaccine was authorized in October 2021, which is likely to have boosted sales.
Improvement in sales of some other key drugs like Xarelto seen in the past few quarters is likely to have continued into the first quarter. The Zacks Consensus Estimate for Xarelto is $607 million.
Rising competitive pressure in the United States to new oral competition is likely to have hurt sales of key drug, Imbruvica in the first quarter. The Zacks Consensus Estimate for Imbruvica is $1.13 billion.
Generic/biosimilar competition for drugs like Zytiga, Procrit/Eprex and Remicade is likely to have hurt the top line.
The Zacks Consensus Estimate for J&J’s Pharmaceuticals unit is $13.8 billion.
With regard to the Medical Devices segment, COVID-19 headwinds and hospital staffing shortages are likely to have continued to hurt procedure volume trends in the first quarter. The Zacks Consensus Estimate for J&J’s Medical Devices segment is $6.8 billion.
In the Consumer Healthcare segment, the improving trend seen in the last couple of quarters is likely to have continued. However, external supply constraints (due to raw material availability and labor shortages) are likely to have continued to hurt sales of the skin health and beauty franchise.
The Zacks Consensus Estimate for J&J’s Consumer Healthcare segment is $3.58 billion.
J&J plans to separate its Consumer Health segment into a new publicly-traded company
Management might announce key executive leadership appointments for the new Consumer Health company on the first-quarter conference call and may also announce the new company name and headquarters location.
On the fourth-quarter conference call, its new chief executive officer (CEO) Joaquin Duato had said the company is taking a more aggressive stance on M&A activity as its strong cash position will help it pursue tuck-in M&A to grow its business. An update is expected on the first-quarter conference call.
Earnings Whispers
Our proven model predicts an earnings beat for J&J in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: J&J’s Earnings ESP is +1.14% as the Most Accurate Estimate of $2.64 is higher than the Zacks Consensus Estimate of $2.61. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: J&J has a Zacks Rank #3
Other Stocks to Consider
Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around:
Merck (MRK - Free Report) with an Earnings ESP of +4.28% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Merck’s stock has risen 14.4% this year so far. Merck topped earnings estimates in two of the last four quarters. Merk has a four-quarter earnings surprise of 5.33%, on average. MRK is scheduled to release its first-quarter 2022 results on Apr 28.
Lilly (LLY - Free Report) has an Earnings ESP of +7.38% and a Zacks Rank #3.
Lilly’s stock has rallied 9.7% this year so far. Lilly missed earnings estimates in each of the last four quarters. Lilly has a four-quarter negative earnings surprise of 3.92%, on average. LLY is scheduled to release its first-quarter 2022 results on Apr 28.
AbbVie (ABBV - Free Report) with an Earnings ESP of +0.48% and a Zacks Rank #3.
AbbVie’s stock has surged 22.2% in the past year. AbbVie topped earnings estimates in three of the last four quarters. AbbVie has a four-quarter earnings surprise of 2.55%, on average. ABBV is scheduled to release its first-quarter 2022 results on Apr 29.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.